Hunt Anthony 4

What Happened

• Anthony Hunt, a director of BioLife Solutions, received a grant of 8,170 restricted common shares (reported as an award/acquisition) on February 24, 2026. No per-share purchase price or total dollar value is reported (N/A). This is a compensation award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-24; Form 4 filed: 2026-02-26 (timely filing).
• Price: N/A — restricted stock award (no cash paid by insider).
• Shares acquired: 8,170 restricted shares.
• Shares owned after transaction: not disclosed in the provided filing.
• Footnote: Award granted under the BioLife Solutions 2023 Performance Incentive Plan; the restricted stock “fully vests on the first anniversary of the vesting date of January 2, 2026” (i.e., one year after Jan 2, 2026).
• No 10b5-1 plan, tax-withholding, or sale noted in this filing.

Context

• Restricted stock awards are compensation and typically carry vesting conditions and transfer restrictions, so they do not indicate an immediate buy/sell market signal. The shares become unrestricted only after the stated vesting conditions are met.